Huerta-Ramírez S, Paniagua-Pérez A, Castro-Serna D, Ledesma-Velázquez A, Rubio-Guerra A, Vargas-Ayala G

Language: Spanish
References: 19
Page: 175-181
PDF size: 322.40 Kb.

ABSTRACT

Background: Metabolic syndrome is a condition that predisposes to cardiovascular disease and diabetes mellitus. In addition, it can have effects over neoplastic pathologies, liver and pulmonary function. Our objective is to analyze the effect of the metabolic syndrome and its components on pulmonary function. Method: 110 subjects from Mexico City were evaluated and anthropometric measurements, glucose determination, triglycerides and high-density lipoprotein (HDL) cholesterol were made. They underwent a simple spirometry. Diagnosis of metabolic syndrome was made following the NCEP-ATPIII criteria. Results: Of 110 individuals, 90 (82%) were women and 20 men (18%); 71 subjects (65%) presented metabolic syndrome. Subjects with central obesity had a forced vital capacity (FVC) lower than subjects without central obesity (2.72 vs. 3.11 liters; p ‹ 0.05). Those with low HDL had better spirometric results than subjects with normal HDL (FEV1 2.36 vs. 1.85 liters; p ‹ 0.05), FVC (2.95 vs. 2.45 liters; p ‹ 0.05) and FEV1/FVC ratio (0.78 vs.74; p ‹ 0.05). Hypertensive subjects presented lower volumes in FEV1 (1.91 vs. 2.38; p ‹ 0.05) and FVC (2.49 vs. 2.99; p ‹ 0.05). Conclusion: There is no difference between the spirometry volumes of patients with metabolic syndrome versus the metabolically healthy subjects. The only factors associated with a decrease in FEV1 and FVC are central obesity and arterial hypertension. An unexpected finding was the negative correlation between HDL levels and lung function.

REFERENCES

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.

2. Beltrán H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U S. population, 1999-2010. J Am Coll Cardiol. 2013;62:697-703.

3. Wacher NH. Epidemiología del síndrome metabólico. Gac Med Mex. 2009;145:384-91.

4. Brede S, Serfling G, Klement J, Schmid SM, Lehnert H. Clinical scenario of the metabolic syndrome. Visc Med. 2016;32:336-41.

5. Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179:509-16.

6. Baffi CW, Wood L, Winnica D, Strollo PJ, Gladwin MT, Que LG, et al. Metabolic syndrome and the lung. Chest. 2016;149:1525-34.

7. Chen WL, Wang CC, Wu LW, Kao TW, Chan JY, Chen YJ, et al. Relationship between lung function and metabolic syndrome. PLoS One. 2014;9:e108989.

8. Ford ES, Cunningham TJ, Mercado CI. Lung function and metabolic syndrome: findings of National Health and Nutrition Examination Survey 2007-2010. J Diabetes. 2014;6:603-13.

9. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.

10. Reed RM, Iacono A, DeFilippis A, Eberlein M, Girgis RE, Jones S. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J Heart Lung Transplant. 2011;30:674-8.

11. Marquis K, Maltais F, Duguay V, Bezeau AM, LeBlanc P, Jobin J, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2005;25:226-32.

12. Lin WY, Yao CA, Wang HC, Huang KC. Impaired lung function is associated with obesity and metabolic syndrome in adults. Obesity (Silver Spring). 2006;14:1654-61.

13. Yeh F, Dixon AE, Marion S, Shaefer C, Zhang Y, Best LG, et al. Obesity in adults is associated with reduced lung function in metabolic syndrome and diabetes: the Strong Heart Study. Diabetes Care. 2011; 34:2306-13.

14. Bae MS, Han JH, Kim JH, Kim YJ, Lee KJ, Kwon KY. The relationship between metabolic syndrome and pulmonary function. Korean J Fam Med. 2012;33:70-8.

15. Burkart KM, Manichaikul A, Wilk JB, Ahmed FS, Burke GL, Enright P, et al. APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema. Eur Respir J. 2014; 43:1003-17.

16. Gordon S, Durairaj A, Lu JL, Davidson WS. High-density lipoprotein proteomics: identifying new drug targets and biomarkers by understanding functionality. Curr Cardiovasc Risk Rep. 2010;4:1-8.

17. Pian MS, Dobbs LG. Lipoprotein-stimulated surfactant secretion in alveolar type II cells: mediation by heterotrimeric G proteins. Am J Physiol. 1997;273:634-9.

18. Kolleck I, Schlame M, Fechner H, Looman AC, Wissel H, Rüstow B. HDL is the major source of vitamin E for type II pneumocytes. Free Radic Biol Med. 1999;27:882-90.

19. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-35.